Beyond Air

Company Overview

Snapshot

Founded in May 2011 by Amir Avniel and Yossef Av-Gay, Beyond Air operates with 51–200 employees. The company has raised over $69.54 million across 7 funding rounds. In March 2026, Beyond Air announced the resignation of CEO Steve Lisi and the appointment of Robert Goodman as CEO.

Business overview

Beyond Air is a medical device and biopharmaceutical company focused on leveraging nitric oxide's therapeutic properties for respiratory diseases. Its LungFit technology platform generates nitric oxide on-demand from ambient air, delivering it to patients for various lung conditions. The LungFit PH system is FDA-approved and utilizes patented Ionizer technology for unlimited, on-demand nitric oxide delivery, serving markets in healthcare, particularly providers and patients, within the pharmaceuticals and medical devices sectors.

Strategic signal

In June 2026, Beyond Air received a Nasdaq Hearing Panel Decision granting continued listing. This indicates the company is actively addressing compliance requirements, which is a critical signal for investors regarding its ongoing public market presence and operational stability.

Company Intelligence Q&A

What was the outcome of the Nasdaq Hearing Panel Decision in June 2026?

In June 2026, Beyond Air received a Nasdaq Hearing Panel Decision granting the company continued listing.

What significant leadership change occurred in March 2026?

In March 2026, Beyond Air announced the resignation of CEO Steve Lisi and the appointment of Robert Goodman, previously Chief Commercial Officer, as the new CEO.

What was the outcome of Beyond Air's Q3 2026 earnings report?

In February 2026, Beyond Air reported a 105% year-over-year revenue increase to $2.2 million for the fiscal quarter ending December 31, 2025. The company also achieved a gross profit of $300,000 and reduced operating expenses by 36%.

What was the outcome of the agreement to sell NeuroNOS in March 2026?

In March 2026, Beyond Air announced the termination of its agreement to sell its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd.

What was the focus of the private placement in January 2026?

In January 2026, Beyond Air announced a securities purchase agreement with an institutional investor for a private placement, expecting gross proceeds of approximately $5.0 million. Rodman & Renshaw LLC acted as the exclusive placement agent.